ELAN
Price
$14.28
Change
-$0.03 (-0.21%)
Updated
Jun 11, 04:59 PM (EDT)
Capitalization
7.87B
61 days until earnings call
NBIX
Price
$124.13
Change
-$0.64 (-0.51%)
Updated
Jun 11, 04:59 PM (EDT)
Capitalization
13.72B
55 days until earnings call
Interact to see
Advertisement

ELAN vs NBIX

Header iconELAN vs NBIX Comparison
Open Charts ELAN vs NBIXBanner chart's image
Elanco Animal Health
Price$14.28
Change-$0.03 (-0.21%)
Volume$47.5K
Capitalization7.87B
Neurocrine Biosciences
Price$124.13
Change-$0.64 (-0.51%)
Volume$14.29K
Capitalization13.72B
ELAN vs NBIX Comparison Chart
Loading...
ELAN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NBIX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ELAN vs. NBIX commentary
Jun 12, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ELAN is a StrongBuy and NBIX is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 12, 2025
Stock price -- (ELAN: $14.30 vs. NBIX: $124.77)
Brand notoriety: ELAN: Notable vs. NBIX: Not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: ELAN: 106% vs. NBIX: 45%
Market capitalization -- ELAN: $7.87B vs. NBIX: $13.72B
ELAN [@Pharmaceuticals: Other] is valued at $7.87B. NBIX’s [@Pharmaceuticals: Other] market capitalization is $13.72B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.78B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ELAN’s FA Score shows that 0 FA rating(s) are green whileNBIX’s FA Score has 0 green FA rating(s).

  • ELAN’s FA Score: 0 green, 5 red.
  • NBIX’s FA Score: 0 green, 5 red.
According to our system of comparison, NBIX is a better buy in the long-term than ELAN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ELAN’s TA Score shows that 4 TA indicator(s) are bullish while NBIX’s TA Score has 4 bullish TA indicator(s).

  • ELAN’s TA Score: 4 bullish, 5 bearish.
  • NBIX’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, both ELAN and NBIX are a bad buy in the short-term.

Price Growth

ELAN (@Pharmaceuticals: Other) experienced а +6.24% price change this week, while NBIX (@Pharmaceuticals: Other) price change was -0.18% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -0.47%. For the same industry, the average monthly price growth was +13.88%, and the average quarterly price growth was +64.30%.

Reported Earning Dates

ELAN is expected to report earnings on Aug 11, 2025.

NBIX is expected to report earnings on Aug 05, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (-0.47% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NBIX($13.7B) has a higher market cap than ELAN($7.87B). ELAN YTD gains are higher at: 18.084 vs. NBIX (-8.593). NBIX has higher annual earnings (EBITDA): 358M vs. ELAN (-224M). NBIX has more cash in the bank: 1.03B vs. ELAN (352M). NBIX has less debt than ELAN: NBIX (428M) vs ELAN (5.77B). ELAN has higher revenues than NBIX: ELAN (4.42B) vs NBIX (1.89B).
ELANNBIXELAN / NBIX
Capitalization7.87B13.7B57%
EBITDA-224M358M-63%
Gain YTD18.084-8.593-210%
P/E RatioN/A57.20-
Revenue4.42B1.89B234%
Total Cash352M1.03B34%
Total Debt5.77B428M1,349%
FUNDAMENTALS RATINGS
ELAN vs NBIX: Fundamental Ratings
ELAN
NBIX
OUTLOOK RATING
1..100
7622
VALUATION
overvalued / fair valued / undervalued
1..100
91
Overvalued
72
Overvalued
PROFIT vs RISK RATING
1..100
10080
SMR RATING
1..100
8160
PRICE GROWTH RATING
1..100
4248
P/E GROWTH RATING
1..100
9335
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NBIX's Valuation (72) in the Biotechnology industry is in the same range as ELAN (91) in the Agricultural Commodities Or Milling industry. This means that NBIX’s stock grew similarly to ELAN’s over the last 12 months.

NBIX's Profit vs Risk Rating (80) in the Biotechnology industry is in the same range as ELAN (100) in the Agricultural Commodities Or Milling industry. This means that NBIX’s stock grew similarly to ELAN’s over the last 12 months.

NBIX's SMR Rating (60) in the Biotechnology industry is in the same range as ELAN (81) in the Agricultural Commodities Or Milling industry. This means that NBIX’s stock grew similarly to ELAN’s over the last 12 months.

ELAN's Price Growth Rating (42) in the Agricultural Commodities Or Milling industry is in the same range as NBIX (48) in the Biotechnology industry. This means that ELAN’s stock grew similarly to NBIX’s over the last 12 months.

NBIX's P/E Growth Rating (35) in the Biotechnology industry is somewhat better than the same rating for ELAN (93) in the Agricultural Commodities Or Milling industry. This means that NBIX’s stock grew somewhat faster than ELAN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ELANNBIX
RSI
ODDS (%)
Bearish Trend 2 days ago
68%
Bearish Trend 2 days ago
70%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
76%
Bearish Trend 2 days ago
70%
Momentum
ODDS (%)
N/A
Bullish Trend 2 days ago
76%
MACD
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
57%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
66%
Bearish Trend 2 days ago
62%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
64%
Bullish Trend 2 days ago
70%
Advances
ODDS (%)
Bullish Trend 2 days ago
63%
Bullish Trend 3 days ago
72%
Declines
ODDS (%)
Bearish Trend 7 days ago
74%
Bearish Trend 21 days ago
62%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
68%
Bearish Trend 6 days ago
67%
Aroon
ODDS (%)
Bullish Trend 2 days ago
62%
Bullish Trend 2 days ago
58%
View a ticker or compare two or three
Interact to see
Advertisement
ELAN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NBIX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
AVLV67.340.43
+0.64%
Avantis US Large Cap Value ETF
JUNT33.430.07
+0.22%
AllianzIM U.S. Large Cp Buffer10 Jun ETF
DMXF74.730.12
+0.16%
iShares ESG Advanced MSCI EAFE ETF
OBIL50.030.03
+0.05%
US Treasury 12 Month Bill ETF
RAYD35.04-0.22
-0.61%
Rayliant Quantitative Dev Mkt Eq ETF